Tag: SFA

FastWave Medical announces successful 30-day first-in-human data on peripheral IVL technology

FastWave Medical has announced the 30-day results of its first-in-human (FIH) study using the company's differentiated peripheral intravascular lithotripsy (IVL) technology. This was a...

‘Connect the world’ session at LINC 2023 projects “outstanding” first-release data...

The 'Connect the world: Japan' session at this year’s Leipzig Interventional Course (LINC 2023, 6–9 June, Leipzig, Germany)—in collaboration with the Japanese Endovascular...
detour system

US FDA approves Endologix’s Detour System for treating complex PAD

Endologix has announced in a press release that the US Food and Drug Administration (FDA) has granted approval for the Detour System to treat...
chocolate

Chocolate Touch drug-coated angioplasty balloon for treatment of peripheral artery disease...

Genesis MedTech Group announced that the US Food and Drug Administration (FDA) has approved the Chocolate Touch drug-coated balloon (DCB) percutaneous transluminal angioplasty (PTA)...
SIRONA

SIRONA trial enrolment completed

Concept Medical has announced the successful completion of enrolment for the SIRONA randomised controlled trial (RCT) investigating the use of its Magic Touch PTA...
endologix

Endologix submits premarket approval application to FDA Detour system

Endologix has announced the submission of a premarket approval (PMA) application requesting approval for the Detour system to the US Food and Drug Administration...

Evidence in the SFA: DES ‘will be the standard of care’...

NOTE: This video is ONLY available to watch in selected countries and geographies Marianne Brodmann (Medical University of Graz, Division of Angiology, Austria) talks...
TOP 10

Interventional News’ top 10 most popular items of March 2022

The March top 10 features news that the US trial of the LimFlow system designed to prevent amputations has completed enrolment. Other highlights include two...

Evidence in the SFA: Eluvia has a “significantly better” patency rate...

NOTE: This video is ONLY available to watch in selected countries and geographies Gunnar Tepe (interventional radiologist, Germany) discusses the results and subsequent impact...

Evidence in the SFA: Considering the data when making decisions for...

NOTE: This video is ONLY available to watch in selected countries and geographies  Koen Deloose (vascular surgeon, Belgium) looks at the evidence needed in order...

S.M.A.R.T. Radianz vascular stent system approved for transradial use in the...

Cordis recently announced that the US Food and Drug Administration (FDA) has approved the S.M.A.R.T. Radianz vascular stent system, a self-expanding stent purposefully engineered...
Lorenzo Patrone shares with Blearning at CIRSE, the benefits of using the OUTBACK™ Elite Re-entry Catheter

OUTBACK™ Elite Re-entry catheter highly effective at saving limbs in extreme...

 Lorenzo Patrone (London, UK) shares with Blearning at CIRSE 2019 (7–11 September, Barcelona, Spain) the benefits of using the OUTBACK™ Elite Re-entry Catheter (Cordis,...

Terumo gets CE mark for Kanshas drug-coated balloon catheter for lower...

Terumo has announced receiving the CE mark for its Kanshas drug-coated balloon catheter used in the treatment of lower extremity peripheral arterial disease. With...
Purple drug-coated balloon in an s shape

Medtronic receives US FDA clearance for 200mm and 250mm IN.PACT Admiral...

Medtronic has announced that it has received US FDA approval for 200mm and 250mm lengths of the IN.PACT Admiral drug-coated balloon (DCB) to treat...

LINC 2018 data highlight IN.PACT Admiral as safe and effective treatment...

Medtronic added to its robust body of clinical evidence supporting the IN.PACT Admiral drug-coated balloon with new presentations that demonstrated durable and consistent clinical...

Positive 24-month TOBA results presented at VEITHsymposium

Intact Vascular has announced that positive single centre twenty-four month results from its TOBA (Tack optimised balloon angioplasty) clinical study were presented at VEITHsymposium...

Lutonix registry data confirm durability of drug-coated balloon treatment in superficial...

The 24-month results of the worldwide experience with Lutonix 035 drug-coated balloon (CR Bard/Beckton Dickenson) were published online in August in JACC: Cardiovascular Interventions....